I. Hualing Medicine
Hualing Medicine is the first company in the world to realize the clinical research and development of glucokinase activator (GKA) for blood glucose sensor. It has established the technical standard and clinical medication scheme of "restoring perception, reshaping steady state and fundamentally treating diabetes" and achieved the breakthrough of "from 0 to 1", the first new diabetes drug in China. On April 23, Hualing Pharmaceutical announced that the NDA application submitted by Dozza, the first new diabetes drug, had been accepted by the New Drug Evaluation Center of the State Pharmaceutical Products Administration. Dozza Gliadine became the first glucokinase activator diabetes treatment drug in the world to submit a new drug listing application, and it is expected to become the first new drug listed in China in the world.
Second, it is not just a single drug application.
This declaration is not only a single drug application of Dosa, but also a clinical trial combined with metformin, which is declared together. Chen Li said that Dozza can be combined with the mainstream drugs used in the treatment of diabetes theoretically because its mechanism of action is at the "pyramid tip". At present, Hualing Medicine has completed the joint drug trials of Dozza, Englenet and Sigliptin. The experimental results show that the combination has obvious synergistic effect, and clinical trials with GLP- 1 receptor agonist and insulin are planned.
Hualing Pharmaceutical Technology (Shanghai) Co., Ltd. is a global biotechnology company based in China. 20 1 1 was established in Zhangjiang, Shanghai and listed in Hong Kong on 20 18. Adhering to the tenet of "patients first, innovation first, and medicine for the people", Hualing Medicine has established the operation mode of "combining traditional Chinese and western medicine, innovating jointly, enjoying * * * * and winning", adhered to the management principle of "high standard, high quality and creating high value", and achieved "world first and China first".